32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma
Journal of Translational Medicine2020Vol. 18(1), pp. 295–295
Citations Over TimeTop 10% of 2020 papers
Xiaoyu Liu, Fang Gao, Longwei Jiang, Meng Jia, Lei Ao, Ming Lü, Liming Gou, Mitchell Ho, Shaochang Jia, Fei Chen, Wei Gao
Abstract
Our study provides a rationale for 32A9 as a promising GPC3-specific antibody candidate for HCC immunotherapy.
Related Papers
- A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.(2003)
- → Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 scFv-TRAIL(2019)18 cited
- → Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells(2023)6 cited
- Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.(2013)
- → chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts(2007)28 cited